Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01621607 · ClinicalTrials.gov registry record
Individual Differences in Reward and Impulse Control
A clinical trial of Drug Addiction and Vulnerability to Substance Addiction, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- 89
- Enrollment target
- 1
- Study location
NCT01621607: Completed study of Drug Addiction and Vulnerability to Substance Addiction, sponsored by National Institute on Drug Abuse (NIDA).
NCT01621607 is a study of Drug Addiction and Vulnerability to Substance Addiction that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 89 participants, below the 101-participant average among 13 other Drug Addiction trials with a reported enrollment target (12% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01621607, a study of Drug Addiction and Vulnerability to Substance Addiction, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- 89 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- The risk for becoming addicted to drugs varies among individual, even those using similar drugs in a similar way. It is not known why some people become addicted and others do not. Studies suggest that some genes may increase the risk of addiction. Negative life experiences may also affect the risk of addiction. Researchers want to test smokers and nonsmokers to study genetic and brain function traits that may lead to drug addiction. Objectives: \- To understand brain function in people who may be at a higher risk of drug addiction. Eligibility: * Healthy volunteers between 18 and 55 years of age. * Smokers (10 to 30 cigarettes per day for more than 2 years) and nonsmokers will be eligible. Design: * Participants will be screened with a physical exam and medical history. They will be tested for drug and alcohol use. A blood sample will be collected. * The study will involve one visit. Participants will have a magnetic resonance imaging (MRI) scan. * At the visit, participants will answer questions about their health and drug use habits. They will then be trained on the tasks they will do during the MRI scan. After the training, they will have the scan and perform the tasks. The scan and tasks will look at brain function related to rewards and impulsiveness. * Other computer tests will be given after the scan. These tests will measure learning, memory, and impulsiveness.
Conditions Studied
Study Locations (1)
Maryland
- National Institute on Drug Abuse - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2012-06-08 |
| Est. Completion | 2017-10-03 |
What the finished NCT01621607 record still lists
NCT01621607 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 101-participant average among 13 other Drug Addiction trials with a reported enrollment target (12% lower).
The record links to 2 conditions, with Drug Addiction appearing as the primary indexed condition, and to 0 interventions.
NCT01621607 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01621607 about?
NCT01621607 is a clinical study titled "Individual Differences in Reward and Impulse Control". Background: \- The risk for becoming addicted to drugs varies among individual, even those using similar drugs in a similar way. It is not known why some people become addicted and others do not. Studies suggest that some genes may increase the risk of addiction. Negative life experiences may also ...
What is the current status of trial NCT01621607?
This trial is currently completed. The enrollment target is 89 participants. The study started on 2012-06-08. Estimated completion is 2017-10-03.
What conditions does trial NCT01621607 study?
This clinical trial studies the following conditions: Drug Addiction, Vulnerability to Substance Addiction.
Who is sponsoring clinical trial NCT01621607?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01621607 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Addiction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01621607's enrollment target sits among peer trials
89 7th of 13 higher than 7 of 13 other Drug Addiction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Drug Addiction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-Term Treatment of Opioid Use Disorder
RECRUITING · NA
-
Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder
RECRUITING
-
AWAITS: A Web-based E-health Application for Active Illicit Opioid Users
COMPLETED · NA
-
HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of Biomarkers
COMPLETED
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
-
Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI